Trial results for atezolizumab in combination with other therapies for newly diagnosed metastatic prostate cancer were posted on ClinicalTrials.gov on 2026-04-24. The Phase 2 study enrolled 28 participants to evaluate the addition of atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment.
Background
The study investigated atezolizumab in combination with abiraterone acetate or enzalutamide, a GnRH analog, and radiation therapy. This regimen was explored for men with newly diagnosed hormone-sensitive metastatic prostate cancer.
Trial design
The study (NCT04262154) was a Phase 2 trial that enrolled 28 participants. It investigated the addition of atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment with abiraterone acetate, prednisone, and a GnRH analog for men with newly diagnosed metastatic prostate cancer. The study aimed to assess the safety and efficacy of this combined approach and determine if it performed better than standard treatment alone.
Key results
Results for the outcome 'Failure-free Rate at 2 Years' were reported for two cohorts. For Cohort 1, participant counts were recorded as 13 Participants and 7 Participants. For Cohort 2, participant counts were recorded as 7 Participants and 1 Participant.
What this means
The posted results provide initial data from a Phase 2 investigation into a combination therapy for metastatic prostate cancer. While specific comparative efficacy data or statistical analyses are not detailed in the available outcome measurements, the trial explored the potential benefits of adding atezolizumab and SBRT to existing standard treatments. Clinicians and researchers can review these results to understand the reported participant counts for the 'Failure-free Rate at 2 Years' outcome.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04262154, titled 'Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer,' were posted on 2026-04-24 on clinicaltrials.gov.